NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
November 2, 2023 in Publications

Journal for ImmunoTherapy of Cancer: Local Administration of Large Surface Area Microparticle Docetaxel is Associated with Anti-tumor Immunomodulation Across Multiple Tumor Types

NanOlogy 5 Like Post Comments Off on Journal for ImmunoTherapy of Cancer: Local Administration of Large Surface Area Microparticle Docetaxel is Associated with Anti-tumor Immunomodulation Across Multiple Tumor Types
Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal